China’s Strategic Advance in the Global Biosimilars Market: Implications for Biopharma Competition and Innovation

Trade & Industry, , , , , ,

China has transitioned from a generics and API producer to a formidable global competitor in biosimilars, securing international regulatory approvals and forming strategic partnerships that enhance its presence in key markets. This evolution signals a broader shift in China’s pharmaceutical industry towards innovation, quality, and global integration.

READ MORE

Brazil’s Semaglutide Patent Expiry: A Turning Point for Domestic Pharmaceutical Competitiveness

Trade & Industry, , , , , ,

The expiration of the semaglutide patent in Brazil is catalyzing a shift in the country’s pharmaceutical landscape, enabling local manufacturers to produce biosimilar alternatives to global blockbusters like Novo Nordisk’s Ozempic. This development not only promises enhanced drug accessibility but also signals a maturation of Brazil’s pharmaceutical industry amid growing global competition.

READ MORE